Switching from protease inhibitor-based-HAART to a protease inhibitor-sparing regimen is associated with improved specific HIV-immune responses in HIV-infected children

AIDS

Volumn 20, Issue 14, 2006, Pages 1893-1896

  Pensieroso, Simone ^a   Romiti, Maria Luisa ^a   Palma, Paolo ^a,b   Castelli Gattinara, Guido ^b   Bernardi, Stefania ^b   Freda, Elio ^a   Rossi, Paolo ^a,b   Cancrini, Caterina ^a,b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; T LYMPHOCYTE RECEPTOR;

ADOLESCENT; ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SUBSTITUTION; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LYMPHOCYTE PROLIFERATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; VIRUS IMMUNITY; VIRUS LOAD;

ADOLESCENT; ANTIGENS, VIRAL; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD8-POSITIVE T-LYMPHOCYTES; CHILD; CHILD, PRESCHOOL; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; PROSPECTIVE STUDIES; RECEPTORS, ANTIGEN, T-CELL; REVERSE TRANSCRIPTASE INHIBITORS; T-LYMPHOCYTES; TREATMENT OUTCOME; VIRAL LOAD;

EID: 33748499796     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000244211.33876.6f     Document Type: Article

References (10)

1. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Sattern GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-860.
2. Romiti ML, Cancrini C, Castelli-Gattinara G, Di Cesare S, Ciaffi P, Bernardi S, et al. Kinetics of the T-cell receptor CD4 and CD8 V beta repertoire in HIV-1 vertically infected infants early treated with HAART. AIDS 2001; 15:2075-2084.
3. Resino S, Correa R, Bellon JM, Sanchez-Ramon S, Munoz-Fernandez MA. Characterizing immune reconstitution after long-term highly active antiretroviral therapy in paediatric AIDS. AIDS Res Hum Retroviruses 2002; 18:1395-1406.
4. McComsey GA, Leonard E. Metabolic complications of HIV therapy in children. AIDS 2004; 18:1753-1768.
5. Kim JH, Mascola JR, Ratto-Kim S, VanCott TC, Loomis-Price L, Cox JH, et al. Selective increases in HIV-specific neutralizing antibody and partial reconstitution of cellular immune responses during prolonged, successful drug therapy of HIV infection. AIDS Res Hum Retroviruses 2001; 17:1021-1034.
6. Maslanka K, Piatek T, Gorski J, Yassai M, Gorski J. Molecular analysis of T cell repertoires. Spectratypes generated by multiplex polymerase chain reaction and evaluated by radioactivity or fluorescence. Hum Immunol 1995; 44:28-34.
7. Bonjoch A, Paredes R, Galvez J, Miralles C, Videla S, Martinez E, et al. Antiretroviral treatment simplification with 3 NRTIs or 2 NRTIs plus nevirapine in HIV-1-infected patients treated with successful first-line HAART. J Acquir Immune Defic Syndr 2005; 39:313-316.
8. Legrand FA, Abadi J, Jordan KA, Davenport MP, Deeks SG, Fennelly GJ, et al. Partial treatment interruption of protease inhibitors augments HIV-specific immune response in vertically infected paediatric patients. AIDS 2005; 19:1575-1585.
9. Piccinini M, Rinaudo MT, Anselmino A, Buccinnà B, Ramondetti C, Dematteis A, et al. The HIV protease inhibitors nelfinavir and saquinavir, but not a variety of HIV reverse transcriptase inhibitors, adversely affect human proteasome function. Antiviral Ther 2005; 10:215-223.
10. Andre P, Groettrup M, Klenerman P, de Giuli R, Booth BL Jr, Cerundolo V, et al. An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses. Proc Natl Acad Sci U S A 1998; 95:13120-13124.